Proposed Changes to 340B May Curb Hospital Abuses

Lisa Miller
Published: Saturday, Sep 02, 2017
Ted Okon

Ted Okon
Outpatient branded drug sales in the 340B Drug Pricing Program now amount to almost 8% of the total market, well up from 5.4% in 2012, according to a whitepaper from the Berkeley Research Group.1 The new figure highlights the dramatic growth of 340B and fuels concerns about the abuse that government officials believe is rampant in the program.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x